GlaxoSmithKline unveils $139M U.S. plant for Benlysta production
GlaxoSmithKline manufacturing is definitely on a role. A week after christening a new manufacturing plant in Pennsylvania, GSK has officially opened one in Maryland.
The $139 million plant at its Rockville, Maryland site was built to add capacity for GSK’s lupus-fighter Benlysta, a drug that has been prescribed to 59,000 patients in the U.S. since its introduction in 2011.
GSK chose to retrofit an existing building at the Maryland site, where it already had expertise in producing the injected or infused drug. The investment was used to pay for the demolition of existing suites and the engineering, installation and validation of new equipment.